Middle East & Africa Sarcoma Drugs Market Size & Outlook

The sarcoma drugs market in Middle East & Africa is expected to reach a projected revenue of US$ 81.3 million by 2030. A compound annual growth rate of 9.3% is expected of Middle East & Africa sarcoma drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$43.6
Forecast, 2030 (US$M)
$81.3
CAGR, 2024 - 2030
9.3%
Report Coverage
Middle East & Africa

Middle East & Africa sarcoma drugs market, 2018-2030 (US$M)

Middle

MEA sarcoma drugs market highlights

  • The MEA sarcoma drugs market generated a revenue of USD 43.6 million in 2023.
  • The market is expected to grow at a CAGR of 9.3% from 2024 to 2030.
  • In terms of segment, chemotherapy was the largest revenue generating type in 2023.
  • Chemotherapy is the most lucrative type segment registering the fastest growth during the forecast period.


MEA data book summary

Market revenue in 2023USD 43.6 million
Market revenue in 2030USD 81.3 million
Growth rate9.3% (CAGR from 2023 to 2030)
Largest segmentChemotherapy
Fastest growing segmentChemotherapy
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationChemotherapy
Key market players worldwidePfizer Inc, Novartis AG ADR, Eli Lilly and Co, Bayer AG, Eisai Co Ltd, Johnson & Johnson, Merck & Co Inc, Daiichi Sankyo Co Ltd


Other key industry trends

  • In terms of revenue, MEA region accounted for 3.1% of the global sarcoma drugs market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 519.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Sarcoma Drugs Market Scope

Sarcoma drugs market segmentation & scope
Chemotherapy
Targeted Therapy and others
Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Countries
U.S.
Canada
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Japan
China
India
Australia
South Korea
Thailand
Mexico
Brazil
South Africa
Saudi Arabia
UK
Argentina
UAE
Kuwait

Sarcoma Drugs Market Companies

Name Profile # Employees HQ Website

Middle East & Africa sarcoma drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sarcoma drugs market will help companies and investors design strategic landscapes.


Chemotherapy was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Middle East & Africa sarcoma drugs market based on chemotherapy covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Middle East & Africa sarcoma drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa sarcoma drugs market databook

  • Our clientele includes a mix of sarcoma drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa sarcoma drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa sarcoma drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more